Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

Oramed is moving on to Phase 2b with

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
trendmkr Member Profile
 
Followed By 12
Posts 911
Boards Moderated 0
Alias Born 05/29/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/6/2019 6:02:01 AM
Oramed Appoints Dr. Arie Mayer to Board of Directors PR Newswire (US) - 12/5/2019 9:12:00 AM
Oramed to Present a Scientific Poster at International Diabetes Federation Congress PR Newswire (US) - 12/2/2019 8:25:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 11/27/2019 4:28:28 PM
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology PR Newswire (US) - 11/21/2019 8:27:00 AM
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:18:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/5/2019 4:49:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/5/2019 4:42:36 PM
Oramed to Present at Three Upcoming Conferences PR Newswire (US) - 9/3/2019 8:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 5:28:25 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/6/2019 1:29:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 6:08:14 AM
trendmkr   Monday, 01/09/17 01:12:01 PM
Re: None
Post # of 525 
Oramed is moving on to Phase 2b with an oral GLP-1 formulation in 2017, and positive results there could have the effect of reinforcing investor confidence in its technology despite Novo Nordisk pulling out of the insulin side of the equation. Novo Nordisk leaving the space could be a positive for Oramed, given that it will now have no major competitor for oral insulin, in the event that its candidate ORMD 0801 makes it to market.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist